Loading...

SPRB SPRUCE BIOSCIENCES INC Capital Structure Changes 8-K Filing

SPRC

SPRB

SPRUCE BIOSCIENCES INC

(SPRB)

2026 8-K

Agreement Termination

New Sales Agreement

Positive Study Results

Loan Agreement Details

Director Appointment

Director Resignation & Repr...

Financial Results Announced

Director Departure

Private Placement News

Financial Results

Reverse Stock Split

Voluntary Delisting

Equity Offerings

Financial Statements

Management Changes

Corporate Update

Management Change

Trial Discontinuation

Q3 Financial Results

Nasdaq Extension

Q2 Financial Results

Asset Purchase Agreement

Phase 2 Clinical Trial Results

Earnings Reports

Delisting Notice

Financial Results Announcement

Financial Update

Financial Results Announcement

Financial Results and Clini...

Annual Meeting Results

Resignation and Appointments

Earnings Report

Earnings Report

Private Placement of Common...

Collaboration and License A...

External Links:

On January 7, 2026, Spruce Biosciences, Inc. entered into a $50 million Loan Agreement to support its enzyme therapy development for Sanfilippo Syndrome Type B; as of December 31, 2025, the company had approximately $48.9 million in cash and equivalents.

AI Assistant

SPRUCE BIOSCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.